search
Back to results

Randomized Clinical Trial of Nasal Turbinate Reduction to Improve Continuous Positive Airway Pressure (CPAP) Outcomes for Sleep Apnea (TURBO)

Primary Purpose

Sleep Apnea Syndromes, Nasal Obstruction, Turbinate Hypertrophy

Status
Completed
Phase
Phase 2
Locations
United States
Study Type
Interventional
Intervention
Radiofrequency Turbinate Reduction
Sham RF
Sponsored by
University of Washington
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Sleep Apnea Syndromes focused on measuring Sleep Apnea, Sleep disordered breathing, Nasal Obstruction, Turbinate, Radiofrequency, Continuous positive airway pressure, CPAP, Sleep surgery

Eligibility Criteria

18 Years - 80 Years (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • Age 18-80 years
  • Newly diagnosed obstructive sleep apnea (apnea-hypopnea index >= 5 events/hour)
  • CPAP therapy recommended
  • Persistent bilateral inferior turbinate hypertrophy
  • American Society of Anesthesiologists Class I-III
  • Ability to give informed consent
  • Ability and willingness to complete the study protocol
  • Fluency in verbal and written English

Exclusion Criteria:

  • Previous surgical turbinate treatment
  • Other nasal disorders (i.e. recurrent epistaxis, desiccated or crusted mucosa, severe bilateral obstructing septal deformity, or obstructing polyposis)
  • Active respiratory tract infections
  • Coagulopathy
  • Severe psychiatric comorbidity (taking anti-psychotic medication)
  • American Society of Anesthesiologists Class IV or V
  • Pregnancy
  • No telephone
  • Plans of moving during the study period
  • Known contraindication to lidocaine with epinephrine, oxymetazoline, or acetaminophen

Sites / Locations

  • UW Sleep Disorders Center at Harborview Medical Center
  • Virginia Mason Medical Center
  • University of Washington General Clinical Research Center

Arms of the Study

Arm 1

Arm 2

Arm Type

Active Comparator

Sham Comparator

Arm Label

1

2

Arm Description

Active RF treatment

Sham RF treatment

Outcomes

Primary Outcome Measures

Nasal minimum cross-sectional area (measured objectively with acoustic rhinometry)
CPAP use (measured objectively as pressure-on use)
Sleep Apnea Quality of Life Index (change measured with Then Test technique)

Secondary Outcome Measures

Secondary Nasal Outcome Measures: peak inspiratory flow, resistance (rhinomanometry), endoscopy, smell identification test, nasal obstruction symptom evaluation (NOSE) scale, and other nasal treatment history
Secondary CPAP Outcome Measures: acceptance, subjective tolerance, pressure, leak, residual breathing events (measured by CPAP device)
Secondary Clinical Outcome Objective Measures: vigilance (psychomotor vigilance task monitor), blood pressure, and plasma C-reactive protein (cardiovascular risk biomarker)
Secondary Clinical Outcome Subjective Measures: Quality of Life Change, Symptoms of Nocturnal Obstruction & Related Events (SNORE-25) Scale, Pittsburgh Sleep Quality Index, Epworth Sleepiness Scale, and Short Form-36 version 2
Adverse events

Full Information

First Posted
July 17, 2007
Last Updated
June 17, 2013
Sponsor
University of Washington
Collaborators
National Institutes of Health (NIH)
search

1. Study Identification

Unique Protocol Identification Number
NCT00503802
Brief Title
Randomized Clinical Trial of Nasal Turbinate Reduction to Improve Continuous Positive Airway Pressure (CPAP) Outcomes for Sleep Apnea
Acronym
TURBO
Official Title
Turbinate Reduction & CPAP Use: A Randomized Blinded OSA (TURBO) Trial
Study Type
Interventional

2. Study Status

Record Verification Date
June 2013
Overall Recruitment Status
Completed
Study Start Date
July 2007 (undefined)
Primary Completion Date
June 2011 (Actual)
Study Completion Date
June 2011 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
University of Washington
Collaborators
National Institutes of Health (NIH)

4. Oversight

Data Monitoring Committee
Yes

5. Study Description

Brief Summary
Obstructive sleep apnea occurs in 2-4% of middle age adults and results in significant morbidity and mortality. The first line therapy is provision of continuous positive airway pressure (CPAP) via a nasal mask chronically. Nasal resistance related to nasal turbinate enlargement may compromise CPAP treatment. This randomized double-blind sham-placebo-controlled trial tests the hypothesis that nasal turbinate reduction improves the nasal passage, CPAP use, and sleep apnea quality of life in newly diagnosed sleep apnea patients who are recommended CPAP therapy.
Detailed Description
Obstructive sleep apnea syndrome afflicts at least 2 - 4% of adults and is associated with significant morbidity and mortality. Continuous positive airway pressure (CPAP) therapy is the primary treatment for sleep apnea in adults, but non-adherence to CPAP limits its effectiveness. Even with maximal medical therapy, nasal obstruction is common in sleep apnea patients and may hamper both CPAP adherence and efficacy. However, the most common cause of nasal obstruction in sleep apnea patients (turbinate hypertrophy) is surgically correctable. Treatment of nasal obstruction may lead to more successful use of CPAP. The long-term goal of the proposed research is to develop a novel, multi-disciplinary, multi-modal approach to therapy, in order to improve clinically important treatment outcomes for sleep apnea. The short-term objectives of this proposal are to: Quantify the effect of nasal turbinate reduction on the nasal airway; Determine whether turbinate reduction increases CPAP use or efficacy; and Determine whether turbinate reduction positively influences CPAP treatment outcomes. We will employ a single-site, randomized, double-blind, sham-placebo-controlled trial to test the hypotheses that turbinate reduction: increases nasal airway cross-sectional area; increases mean nightly objective CPAP use; and improves sleep apnea quality of life 3 months after CPAP titration. We will use the radiofrequency turbinate reduction surgical technique, which allows ethical randomization and effective blinding. Three, six, and 12 months after turbinate reduction and CPAP titration we will measure the change in the minimal nasal cross-sectional area, level of CPAP use, and improvement in sleep apnea quality of life. Secondary outcomes will capture this treatment's broader impact on the nose, CPAP, and sleep apnea. If turbinate reduction can be shown to improve sleep apnea outcomes through increased use or efficacy of CPAP therapy, this trial will demonstrate the value and effectiveness of a novel, multidisciplinary, combined medical-surgical approach to the management of obstructive sleep apnea syndrome.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Sleep Apnea Syndromes, Nasal Obstruction, Turbinate Hypertrophy
Keywords
Sleep Apnea, Sleep disordered breathing, Nasal Obstruction, Turbinate, Radiofrequency, Continuous positive airway pressure, CPAP, Sleep surgery

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 2
Interventional Study Model
Parallel Assignment
Masking
ParticipantCare ProviderInvestigator
Allocation
Randomized
Enrollment
242 (Actual)

8. Arms, Groups, and Interventions

Arm Title
1
Arm Type
Active Comparator
Arm Description
Active RF treatment
Arm Title
2
Arm Type
Sham Comparator
Arm Description
Sham RF treatment
Intervention Type
Procedure
Intervention Name(s)
Radiofrequency Turbinate Reduction
Intervention Description
Radiofrequency Turbinate Reduction
Intervention Type
Procedure
Intervention Name(s)
Sham RF
Intervention Description
The steps of the procedure are as follows: 1) application of topical anesthetic to the turbinate mucosa bilaterally; 2) injection of 1.0 ml of lidocaine 1% with epinephrine 1:100,000 with a 30-gauge needle into each inferior turbinate anteriorly; 3) delay five minutes for local anesthetic to take full effect; 4) re-insertion of the anesthetic needle to check for complete anesthesia on one side, and injection of another 1.0 ml of lidocaine 1% with epinephrine 1:100,000 5) placement of the radiofrequency electrode (23-gauge, 1 cm long) into the inferior turbinate; 6) delivery of 300 Joules of radiofrequency energy to the turbinate over 29 seconds (no energy will be delivered in sham procedure)7) placement of a cotton pledget (soaked in oxymetazoline solution 0.05%) against the treatment site 8) repeat steps 3 - 8 for the contra-lateral inferior turbinate; 9) removal of the cotton pledgets after several minutes; and 11) observation of hemostasis.
Primary Outcome Measure Information:
Title
Nasal minimum cross-sectional area (measured objectively with acoustic rhinometry)
Time Frame
Primary outcome at 3 months, secondary outcomes at 6 and 12 months
Title
CPAP use (measured objectively as pressure-on use)
Time Frame
Primary outcome at 3 months, secondary outcomes at 6 and 12 months
Title
Sleep Apnea Quality of Life Index (change measured with Then Test technique)
Time Frame
Primary outcome at 3 months, secondary outcomes at 6 and 12 months
Secondary Outcome Measure Information:
Title
Secondary Nasal Outcome Measures: peak inspiratory flow, resistance (rhinomanometry), endoscopy, smell identification test, nasal obstruction symptom evaluation (NOSE) scale, and other nasal treatment history
Time Frame
3, 6, and 12 months
Title
Secondary CPAP Outcome Measures: acceptance, subjective tolerance, pressure, leak, residual breathing events (measured by CPAP device)
Time Frame
3, 6, and 12 months
Title
Secondary Clinical Outcome Objective Measures: vigilance (psychomotor vigilance task monitor), blood pressure, and plasma C-reactive protein (cardiovascular risk biomarker)
Time Frame
3, 6, and 12 months
Title
Secondary Clinical Outcome Subjective Measures: Quality of Life Change, Symptoms of Nocturnal Obstruction & Related Events (SNORE-25) Scale, Pittsburgh Sleep Quality Index, Epworth Sleepiness Scale, and Short Form-36 version 2
Time Frame
3, 6, and 12 months
Title
Adverse events
Time Frame
Any time research participant reports and scheduled evaluations at 3, 6, and 12 months

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
80 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Age 18-80 years Newly diagnosed obstructive sleep apnea (apnea-hypopnea index >= 5 events/hour) CPAP therapy recommended Persistent bilateral inferior turbinate hypertrophy American Society of Anesthesiologists Class I-III Ability to give informed consent Ability and willingness to complete the study protocol Fluency in verbal and written English Exclusion Criteria: Previous surgical turbinate treatment Other nasal disorders (i.e. recurrent epistaxis, desiccated or crusted mucosa, severe bilateral obstructing septal deformity, or obstructing polyposis) Active respiratory tract infections Coagulopathy Severe psychiatric comorbidity (taking anti-psychotic medication) American Society of Anesthesiologists Class IV or V Pregnancy No telephone Plans of moving during the study period Known contraindication to lidocaine with epinephrine, oxymetazoline, or acetaminophen
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Edward M. Weaver, MD, MPH
Organizational Affiliation
University of Washington
Official's Role
Principal Investigator
Facility Information:
Facility Name
UW Sleep Disorders Center at Harborview Medical Center
City
Seattle
State/Province
Washington
ZIP/Postal Code
98104
Country
United States
Facility Name
Virginia Mason Medical Center
City
Seattle
State/Province
Washington
ZIP/Postal Code
98104
Country
United States
Facility Name
University of Washington General Clinical Research Center
City
Seattle
State/Province
Washington
ZIP/Postal Code
98195
Country
United States

12. IPD Sharing Statement

Citations:
PubMed Identifier
11801946
Citation
Powell NB, Zonato AI, Weaver EM, Li K, Troell R, Riley RW, Guilleminault C. Radiofrequency treatment of turbinate hypertrophy in subjects using continuous positive airway pressure: a randomized, double-blind, placebo-controlled clinical pilot trial. Laryngoscope. 2001 Oct;111(10):1783-90. doi: 10.1097/00005537-200110000-00023.
Results Reference
background
PubMed Identifier
16408415
Citation
Li HY, Engleman H, Hsu CY, Izci B, Vennelle M, Cross M, Douglas NJ. Acoustic reflection for nasal airway measurement in patients with obstructive sleep apnea-hypopnea syndrome. Sleep. 2005 Dec;28(12):1554-9. doi: 10.1093/sleep/28.12.1554.
Results Reference
background
PubMed Identifier
16299414
Citation
Sugiura T, Noda A, Nakata S, Yasuda Y, Soga T, Miyata S, Nakai S, Koike Y. Influence of nasal resistance on initial acceptance of continuous positive airway pressure in treatment for obstructive sleep apnea syndrome. Respiration. 2007;74(1):56-60. doi: 10.1159/000089836. Epub 2005 Nov 18.
Results Reference
background
PubMed Identifier
17063739
Citation
Lam DJ, James KT, Weaver EM. Comparison of anatomic, physiological, and subjective measures of the nasal airway. Am J Rhinol. 2006 Sep-Oct;20(5):463-70. doi: 10.2500/ajr.2006.20.2940.
Results Reference
background
PubMed Identifier
14990910
Citation
Stewart MG, Witsell DL, Smith TL, Weaver EM, Yueh B, Hannley MT. Development and validation of the Nasal Obstruction Symptom Evaluation (NOSE) scale. Otolaryngol Head Neck Surg. 2004 Feb;130(2):157-63. doi: 10.1016/j.otohns.2003.09.016.
Results Reference
background
PubMed Identifier
10629486
Citation
Friedman M, Tanyeri H, Lim JW, Landsberg R, Vaidyanathan K, Caldarelli D. Effect of improved nasal breathing on obstructive sleep apnea. Otolaryngol Head Neck Surg. 2000 Jan;122(1):71-4. doi: 10.1016/S0194-5998(00)70147-1.
Results Reference
background
PubMed Identifier
11225287
Citation
Hilberg O, Pedersen OF. Acoustic rhinometry: recommendations for technical specifications and standard operating procedures. Rhinol Suppl. 2000 Dec;16:3-17. Erratum In: Rhinol 2001 Jun;39(2):119.
Results Reference
background
PubMed Identifier
9700127
Citation
Flemons WW, Reimer MA. Development of a disease-specific health-related quality of life questionnaire for sleep apnea. Am J Respir Crit Care Med. 1998 Aug;158(2):494-503. doi: 10.1164/ajrccm.158.2.9712036.
Results Reference
background
PubMed Identifier
11790647
Citation
Flemons WW, Reimer MA. Measurement properties of the calgary sleep apnea quality of life index. Am J Respir Crit Care Med. 2002 Jan 15;165(2):159-64. doi: 10.1164/ajrccm.165.2.2010008.
Results Reference
background
PubMed Identifier
12615790
Citation
Yokoe T, Minoguchi K, Matsuo H, Oda N, Minoguchi H, Yoshino G, Hirano T, Adachi M. Elevated levels of C-reactive protein and interleukin-6 in patients with obstructive sleep apnea syndrome are decreased by nasal continuous positive airway pressure. Circulation. 2003 Mar 4;107(8):1129-34. doi: 10.1161/01.cir.0000052627.99976.18.
Results Reference
background
PubMed Identifier
29800001
Citation
Jara SM, Hopp ML, Weaver EM. Association of Continuous Positive Airway Pressure Treatment With Sexual Quality of Life in Patients With Sleep Apnea: Follow-up Study of a Randomized Clinical Trial. JAMA Otolaryngol Head Neck Surg. 2018 Jul 1;144(7):587-593. doi: 10.1001/jamaoto.2018.0485.
Results Reference
derived
Links:
URL
http://depts.washington.edu/ccor/studies/SleepApnea/mainSARG.shtml
Description
Sleep Apnea Research Group

Learn more about this trial

Randomized Clinical Trial of Nasal Turbinate Reduction to Improve Continuous Positive Airway Pressure (CPAP) Outcomes for Sleep Apnea

We'll reach out to this number within 24 hrs